BridgeBio Pharma BBIO
NASDAQ BBIO
$67.74 +0.19 (+0.28%)
At close: Oct 21, 2026 · 4:00 PM EDT

BridgeBio Pharma (BBIO) Long-Term Debt Repayments (2018 - 2025)

Updated

BridgeBio Pharma (BBIO) posted Long-Term Debt Repayments of $459 million for Q1 2025, down 3.0% from $473.42 million a year earlier.

Analysis

BridgeBio Pharma (BBIO) Long-Term Debt Repayments (2018 - 2025) Analysis & Trends

For FY2024, BridgeBio Pharma's Long-Term Debt Repayments came in at $473.42 million.

  • Annual Long-Term Debt Repayments shows a three-year compound annual growth rate of 56.2% (FY2021 to FY2024).
  • In prior years, BridgeBio Pharma's Long-Term Debt Repayments was $20.49 million in FY2022 (-83.5%) and $124.12 million in FY2021.
  • The Q1 2025 figure stands as the lowest quarterly Long-Term Debt Repayments since Q4 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 873.00 Mn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 1.00 Mn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 2.00 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 5.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 20.00 Mn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 2.46 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 17.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 BridgeBio Pharma 13.26 Bn 10.37 Bn 228.63 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 459.00 Mn
Mar 31, 2024 473.42 Mn
Dec 31, 2021 106.01 Mn
Dec 31, 2018 441,000.00
Sep 30, 2018 639,000.00
API Access

BridgeBio Pharma Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=BBIO&period=max&api_key=YOUR_API_KEY